Analytical Data
-
基因名
PNMA5
- Application
-
别名
PNMA5；KIAA1934；Paraneoplastic antigen-like Protein 5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96PV4
-
表达区间
4-442aa
-
氨基酸序列
TLLEDWCKGMDMDPRKALLIVGIPMECSEVEIQDTVKAGLQPLCAYRVLGRMFRREDNAKAVFIELADTVNYTTLPSHIPGKGGSWEVVVKPRNPDDEFLSRLNYFLKDEGRSMTDVARALGCCSLPAESLDAEVMPQVRSPPLEPPKESMWYRKLKVFSGTASPSPGEETFEDWLEQVTEIMPIWQVSEVEKRRRLLESLRGPALSIMRVLQANNDSITVEQCLDALKQIFGDKEDFRASQFRFLQTSPKIGEKVSTFLLRLEPLLQKAVHKSPLSVRSTDMIRLKHLLARVAMTPALRGKLELLDQRGCPPNFLELMKLIRDEEEWENTEAVMKNKEKPSGRGRGASGRQARAEASVSAPQATVQARSFSDSSPQTIQGGLPPLVKRRRLLGSESTRGEDHGQATYPKAENQTPGREGPQAAGEELGNEAGAGAMSH
-
分子量
64.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PNMA5 protein, a member of the paraneoplastic Ma antigens, has garnered significant interest in cancer research due to its potential role as a tumor-associated antigen. Originally identified in patients with paraneoplastic neurological syndromes, PNMA5 is thought to be involved in the immune response against tumors. Its expression is often upregulated in various types of cancer, including small cell lung cancer and other neuroendocrine tumors, making it a promising target for immunotherapy. Studies have suggested that PNMA5 may elicit an immune response, leading to the production of autoantibodies in affected individuals, which could serve as biomarkers for early cancer detection. The recombinant version of PNMA5 is being explored for use in developing diagnostic tests and therapeutic vaccines aimed at enhancing antitumor immunity. Furthermore, understanding its molecular structure and function could provide insights into its role in oncogenesis and the mechanisms by which cancer evades immune surveillance. Ongoing research is focusing on characterizing the immunogenicity of PNMA5 and exploring its potential applications in targeted cancer therapies, highlighting its significance in the evolving landscape of oncology and personalized medicine.
